Apyx Medical (NASDAQ:APYX) Announces Quarterly Earnings Results

Apyx Medical (NASDAQ:APYX) issued its earnings results on Tuesday. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.03, FiscalAI reports. Apyx Medical had a negative net margin of 30.35% and a negative return on equity of 151.01%. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $19.12 million.

Apyx Medical Stock Up 9.9%

APYX opened at $3.43 on Tuesday. The stock has a market capitalization of $131.16 million, a price-to-earnings ratio of -9.53 and a beta of 1.61. The firm has a 50 day moving average price of $3.74 and a 200-day moving average price of $3.30. Apyx Medical has a twelve month low of $0.76 and a twelve month high of $4.50. The company has a quick ratio of 3.61, a current ratio of 4.44 and a debt-to-equity ratio of 5.69.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on APYX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. Roth Mkm began coverage on Apyx Medical in a research note on Monday, December 15th. They set a “buy” rating and a $6.00 target price on the stock. Citizens Jmp raised Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price for the company in a report on Wednesday, November 12th. Wall Street Zen upgraded Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. Finally, Zacks Research raised Apyx Medical to a “hold” rating in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Apyx Medical currently has an average rating of “Moderate Buy” and an average price target of $7.00.

Institutional Investors Weigh In On Apyx Medical

A number of large investors have recently added to or reduced their stakes in APYX. Citadel Advisors LLC purchased a new stake in Apyx Medical during the 3rd quarter valued at $28,000. Osaic Holdings Inc. purchased a new position in shares of Apyx Medical in the 2nd quarter worth $50,000. Franklin Resources Inc. bought a new stake in shares of Apyx Medical in the third quarter worth $59,000. Hudson Bay Capital Management LP purchased a new stake in Apyx Medical during the fourth quarter valued at $73,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Apyx Medical during the fourth quarter valued at $111,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.